JP6708916B1 - Zhuang family pharmaceutical composition for regulating replenishment and method for preparing the same - Google Patents
Zhuang family pharmaceutical composition for regulating replenishment and method for preparing the same Download PDFInfo
- Publication number
- JP6708916B1 JP6708916B1 JP2020006091A JP2020006091A JP6708916B1 JP 6708916 B1 JP6708916 B1 JP 6708916B1 JP 2020006091 A JP2020006091 A JP 2020006091A JP 2020006091 A JP2020006091 A JP 2020006091A JP 6708916 B1 JP6708916 B1 JP 6708916B1
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- zhuang
- pharmaceutical composition
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
- 230000001105 regulatory effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 53
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000008187 granular material Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 235000014121 butter Nutrition 0.000 claims description 3
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 241000332371 Abutilon x hybridum Species 0.000 claims 1
- 241000723347 Cinnamomum Species 0.000 claims 1
- 241001481760 Erethizon dorsatum Species 0.000 claims 1
- 241000209490 Nymphaea Species 0.000 claims 1
- 235000016791 Nymphaea odorata subsp odorata Nutrition 0.000 claims 1
- 240000003582 Platycodon grandiflorus Species 0.000 claims 1
- 235000017803 cinnamon Nutrition 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 9
- 208000020016 psychiatric disease Diseases 0.000 abstract description 8
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract description 3
- 206010002942 Apathy Diseases 0.000 abstract description 2
- 208000020401 Depressive disease Diseases 0.000 abstract description 2
- 201000003102 mental depression Diseases 0.000 abstract description 2
- 241000208422 Rhododendron Species 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 21
- 229930003944 flavone Natural products 0.000 description 14
- 235000011949 flavones Nutrition 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 12
- 150000002212 flavone derivatives Chemical class 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 12
- 238000005457 optimization Methods 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000003809 water extraction Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- 238000001671 psychotherapy Methods 0.000 description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 5
- 235000005493 rutin Nutrition 0.000 description 5
- 229960004555 rutoside Drugs 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 4
- 235000015096 spirit Nutrition 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 240000008397 Ganoderma lucidum Species 0.000 description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010041235 Snoring Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 208000035874 Excoriation Diseases 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 241001116747 Aglaomorpha coronans Species 0.000 description 1
- 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
- 240000004950 Artemisia lactiflora Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 235000001705 insufficient nutrition Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
【課題】 補気・精神調節用チワン族医薬品組成物及びその調製方法を提供することを課題とする。【解決手段】 本発明は、補気・精神調節用チワン族医薬品組成物を開示し、該組成物は、オウカトウスイレン10〜60重量部、ホウトウクウ10〜50重量部、ガイキョウケツ10〜40重量部、オウキャクガイ10〜30重量部、ニッケイ5〜20重量部、シシ10〜25重量部、シャキョウ10〜25重量部、キキョウ10〜30重量部の原料を用いて調製され、調製方法も提供する。本発明の有利な効果は、以下のとおりである。本発明は、気の流れを調整して虚の状態を改善し、龍路、火路を整えるという明確な効能を有し、精神不振、神気虚耗、精神的・体力的疲労、少気懶言、声低息微などの症状をよりよく改善する補気・精神調節用チワン族医薬品組成物を提供し、その調製方法も提供し、調製方法は、操作しやすく、生薬の効能を十分に発揮することができる。【選択図】なしPROBLEM TO BE SOLVED: To provide a Zhuang family pharmaceutical composition for respiration/psychoregulation and a method for preparing the same. The present invention discloses a Zhiwan pharmaceutical composition for relieving and psychological disorders, wherein the composition comprises 10 to 60 parts by weight of Oukato Suiren, 10 to 50 parts by weight of Baotoku, and 10 to 40 parts by weight of Gaikyou-ketsu. , 10 to 30 parts by weight, Nikkei 5 to 20 parts by weight, Shishi 10 to 25 parts by weight, Rhododendron 10 to 25 parts by weight, and Kyoukyo to 10 to 30 parts by weight, and a preparation method is also provided. Advantageous effects of the present invention are as follows. INDUSTRIAL APPLICABILITY The present invention has a clear effect of adjusting the flow of qi to improve the state of imagination, preparing the dragon road, the fire tract, mental depression, debilitating spirit, physical and physical fatigue, and apathy. Provide a Zhiwan pharmaceutical composition for aspiration/psychoregulation that improves symptoms such as vergence and low breathiness, and provides a method for preparing the composition, which is easy to operate and has sufficient efficacy of a crude drug. Can be demonstrated to. [Selection diagram] None
Description
本発明は、民族医薬の分野に属し、具体的には、補気・精神調節用チワン族医薬品組成物及びその調製方法に関する。 TECHNICAL FIELD The present invention belongs to the field of ethnic medicine, and specifically relates to a Zhuang family pharmaceutical composition for aspiration and psychoregulation and a method for preparing the same.
民族医薬品の重要な部分であるチワン族医薬品は、チワン族が古くから疾患を予防し治療するための有効な手段であり、チワン族の身体的健康や生存発展に重要な役割を果たしてきた。チワン族医学によれば、人体は有機的な全体であり、その各構成部分は密接に関連しており分割できないものである。人体の「巧」(天部)、「廊」(人部)、「胴」(地部)の三部、三道(谷道、気道、水道)、両路(龍路、火路)、内臓、及び「奪」(骨)、「諾」(肉)「嘘」(気)、「勒」(血)などは、いずれも互いに関連し、相互作用し、自然界と同期して機能し、制約及び化生を行い、生死を繰り返し移り変わる。人体に正気が不十分である場合、
瘴、蠱、毒などの毒邪が龍路、火路を介して侵入し、水道、谷道、気道の流れが悪くなり、臓腑骨肉ではバランスが崩れたり、又は栄養を充分に取られなかったりし、天人地という三気がともに壊れていると、さまざまな疾患に罹患しやすくなる。疾患の治療には、チワン族医学は、病因を究明することを強調し、疾患の診断を主とし、適切な処方及び適切な生薬を適用する場合が多く、これは、チワン族医学による治療法の主な特徴の1つである。チワン族医学は、婦人科疾患の治療について豊富な経験を蓄積し、チワン族医学に特有のいくつかの方法、チワン族医薬品の処方は、臨床的に良い結果を達成している。
Zhuang medicines, which are an important part of ethnic medicines, have long been an effective means for the prevention and treatment of diseases in Zhuang and have played an important role in the physical health and survival development of Zhuang. According to Zhuang medicine, the human body is an organic whole, whose constituent parts are closely related and indivisible. Human body "Takumi" (top), "Corridor" (human part), "Torso" (ground), three parts, three ways (valley, airway, water supply), both roads (long road, fire road), internal organs , And “deprivation” (bone), “acceptance” (flesh), “lie” (ki), “bule” (blood), etc. are all related, interacting, functioning in synchronization with the natural world, and being constrained. It also undergoes metaplasia, and changes life and death repeatedly. If your body isn't sane enough,
Poisons, scorpions, poisons, and other toxic invades through dragons and fires, causing poor flow in the water supply, valleys, and respiratory tracts, imbalance in visceral bone and meat, or insufficient nutrition. , If the three spirits of the heavenly land are broken together, they are more likely to suffer from various diseases. For the treatment of diseases, Zhuang medicine emphasizes investigating the etiology, mainly focuses on diagnosis of diseases, and often applies appropriate prescriptions and appropriate herbal medicines. Is one of the main features of. Zhuang medicine has accumulated a wealth of experience in the treatment of gynecological diseases, and some of the unique methods of Zhuang medicine, the prescription of Zhuang medicine, have achieved clinically good results.
チワン族医学によれば、「嘘」(気)を非常に重視し、「嘘」(気)は陽であり、「嘘」(気)は動力であり、「嘘」(気)は機能であり、体の生命の動力の表現である。「嘘内」(気虚)は、主に以下の原因で起こる。一、生まれつきの体質が悪く、両親の体が弱く、妊娠中の栄養のバランスが悪く、又は妊娠中の女性の生活や仕事のリズムが不適切であることに起因して早産したり、産後の育て方が不適切であり、栄養失調が起きる。二、後天の過労、精気の消耗、身体虚弱、又は慢性疾患に罹患して長期にわたって治癒できず、体が邪毒と戦った結果、気血が過度に消耗されることである。三、食事が不適切であり、たとえば辛いもの、冷たいもの、甘いものや脂っこいものを必要以上に摂取したり、又は過量の酒を飲んだりして、谷道へダメージを与え、谷道の受入、消化、吸収の機能の低下を引き起こし、十分に摂取できないか又は水や穀由来の微妙な栄養素を消化して吸収して気に変換できず、気が十分であれば元気があり、逆に気が不十分であれば元気が損なわれ、その結果、精神障害、神気両虚を引き起こし、精神的・体力的疲労、少気懶言、声低息微などの症状が現れる。従って、特に気の流れを調整して虚の状態を改善し、龍路、火路を整え、且つ精神障害、神気両虚、精神的・体力的疲労、少気懶言、声低息微などの症状を著しく改善できる医薬品の開発が非常に重要である。 According to Zhuang medicine, "lie" (ki) is very important, "lie" (ki) is positive, "lie" (ki) is power, and "lie" (ki) is function. Yes, it is an expression of the power of the body's life. "Lie within" (mind) is caused mainly by the following causes. 1.Premature delivery or postpartum due to poor natural constitution, weak parents' parents, poor nutritional balance during pregnancy, or improper rhythm of life or work of pregnant women Inadequate care and malnutrition. Second, the patient suffers from acquired overwork, exhaustion of energy, physical weakness, or chronic illness and cannot be cured for a long period of time. Inappropriate diet, such as spicy food, cold food, sweet food or greasy food more than necessary, or excessive drinking, causing damage to the valley and accepting or digesting it. , Causes a decline in absorption function and cannot be ingested sufficiently or digests and absorbs subtle nutrients derived from water and cereals and cannot be converted into mood. Insufficient energy will result in impaired energy, resulting in mental disorders, divorce, and symptoms such as mental and physical fatigue, snoring, and low voice. Therefore, in particular, it adjusts the flow of qi to improve the state of emptiness, prepares the dragon road, the fire tract, and also has mental disorders, both spirits and spirits, mental/physical fatigue, snoring, and low voice. It is very important to develop a drug that can significantly improve such symptoms.
本発明が解决しようとする技術的課題は、気の流れを調整して虚の状態を改善し、龍路、火路を整えるという効能を有し、精神障害、神気両虚、精神的・体力的疲労、少気懶言、声低息微などの症状をよく改善する補気・精神調節用チワン族医薬品組成物及びその調製方法を提供することである。 The technical problem to be solved by the present invention is to adjust the flow of qi to improve the state of imagination, and to prepare dragon roads and fire routes, and to prevent mental disorders, enthusiasm, and mental It is an object of the present invention to provide a Zhuang family pharmaceutical composition for scavenging/psychoregulation and a method for preparing the same, which improves symptoms such as physical fatigue, snoring, and low breathing.
本発明は、以下の技術案により上記技術的課題を解决する。 The present invention solves the above technical problems by the following technical solutions.
補気・精神調節用チワン族医薬品組成物であって、オウカトウスイレン10〜60重量部、ホウトウクウ10〜50重量部、ガイキョウケツ10〜40重量部、オウキャクガイ10〜30重量部、ニッケイ5〜20重量部、シシ10〜25重量部、シャキョウ10〜25重量部、キキョウ10〜30重量部の原料を用いて調製される。 A Qiwan family pharmaceutical composition for replenishment/psychotherapy, which comprises 10 to 60 parts by weight of Oukatousuren, 10 to 50 parts by weight of banana, 10 to 40 parts by weight of gall butter, 10 to 30 parts by weight of nickname, 5 to 20 parts of nikkei. Parts, 10 to 25 parts by weight of shishi, 10 to 25 parts by weight of persimmon, and 10 to 30 parts by weight of persimmon.
さらに、上記補気・精神調節用チワン族医薬品組成物において、該組成物は、オウカトウスイレン40重量部、ホウトウクウ40重量部、ガイキョウケツ20重量部、オウキャクガイ20重量部、ニッケイ10重量部、シシ20重量部、シャキョウ20重量部、キキョウ20重量部の原料を用いて調製される。本発明の煎剤の調製方法は、上記原料を重量に応じてそれぞれ秤取し、原料を洗浄して選別し、薬鍋に入れ、水を加えて0.5〜1時間浸し、薬液が沸騰するまで強火で煎じた後、弱火に切り替えて20〜25分間煎じ、煎じ汁を濾取する一次煎じステップと、生薬の平面から0.5〜1センチメートル上に常温の水を再度加え、薬液が沸騰するまで強火で煎じた後、弱火に切り替えて15〜20分間煎じ、煎じ汁を濾取する二次煎じステップと、一次煎じと二次煎じで得られた煎じ汁を合わせるステップと、を含む。 Further, in the above-mentioned replenishment/psychoregulatory Zhuang family pharmaceutical composition, the composition comprises 40 parts by weight of Oukatousuiren, 40 parts by weight of Bakuroku, 20 parts by weight of Gaikyo butts, 20 parts by weight of Nikkai, 10 parts by weight of Nikkei, 20 of shishi. It is prepared by using the raw materials of 20 parts by weight, 20 parts by weight of kyoko and 20 parts by weight of kyokyo. In the method for preparing a decoction of the present invention, the above-mentioned raw materials are weighed according to weight, washed and selected, put in a pot, and water is added and immersed for 0.5 to 1 hour to boil the drug solution. After decocting over high heat, switch to low heat and decoct for 20-25 minutes, filter the decoction, and add water at room temperature again 0.5-1 cm above the plane of the crude drug, After decocting on high heat until boiling, switch to low heat and decoct for 15 to 20 minutes, and include a secondary decoction step of filtering the decoction and a step of combining the primary decoction and the decoction obtained from the secondary decoction. ..
本発明の第2の目的は、上記補気・精神調節用チワン族医薬品組成物の調製方法を提供することであり、重量部で秤取される原料に水を10倍加え、1回当たり1時間に3回煎じ、濾過して濃縮し、80℃で減圧乾燥し、粉砕して100メッシュのふるいにかけ、乾燥ペースト粉末にスクロースを加え、均一に混合し、75%エタノールを用いて軟質材料とし(エタノール使用量8%)、15min撹拌し、12メッシュのふるいにかけて造粒し、75℃で4h乾燥し、12メッシュのふるいにかけて整粒し、混合機で均一に混合し、梱包して包装する。 A second object of the present invention is to provide a method for preparing the above-mentioned medicinal composition for replenishment/psychotherapy Zhuang family, in which water is added 10 times to a raw material to be weighed in parts by weight, and 1 time is added to each time. Decoction 3 times per hour, filter and concentrate, dry under reduced pressure at 80°C, crush and sieve through a 100 mesh screen, add sucrose to the dry paste powder, mix evenly, and use 75% ethanol to make a soft material. (Ethanol usage 8%), stir for 15 min, granulate with a 12 mesh sieve, dry at 75°C for 4 h, sieving with a 12 mesh sieve, uniformly mix with a mixer, package and package. ..
さらに、上記補気・精神調節用チワン族医薬品組成物の調製方法において、前記チワン族医薬品組成物の剤形は煎剤である。 Further, in the above-mentioned method for preparing a Zhuang pharmaceutical composition for insufflation/psychotherapy, the dosage form of the Zhuang pharmaceutical composition is a decoction.
本発明に係るチワン族医薬品及び漢方薬組成物に含まれる原料の特徴は、以下のとおりである。 The characteristics of the raw materials contained in the Zhuang medicine and the herbal composition according to the present invention are as follows.
オウカトウスイレン:チワン族医薬名はGosinhvahenjであり、ヒメハギ科植物黄花倒水蓮Polygala aureocauda Dunnの根又は全株に由来する。性味:甘、微温。効能:虚の状態を改善して気の流れを調整して、湿邪を取り除き毒素を排出し、血の流れを促進したり出血を止めたりする。主治:病気後虚弱、産後血虚、脾虚水腫、風湿骨痛、季肋部痛、打撲傷、膣出血、外傷出血などである。 Oukatousuiren: Zhuang medicine name is Gosinhvahenj, which is derived from the roots or whole strains of Polygala aureocauda Dunn, which is a plant of the family Hemelaceae. Taste: sweet, slightly warm. Efficacy: Improves the state of emptiness and regulates the flow of qi, removes the cold and expels toxins, promotes blood flow and stops bleeding. Main cure: Weakness after illness, postpartum blood loss, splenic hydrops, wind and wet bone pain, seasonal rib pain, bruising, vaginal bleeding, traumatic bleeding, etc.
ホウトウクウ:チワン族医薬名はRaethozduzlingzであり、ハリタケ科真菌ヤマブシタケHericium erinaceus(Bull:Fr)Persの子実体に由来する。性味:甘、平。効能:谷道を整え、気の流れを調整して虚の状態を改善する。主治:食滞、気虚、血虚などである。 Hakutoku: The name of the Zhuang medicine is Raethozduzlingz, which is derived from the fruiting body of the fungus Hericium erinaceus (Bull:Fr) Pers, which is a fungus in the family Ganoderma lucidum. Taste: sweet, flat. Efficacy: Improve the imaginary state by adjusting the valley and adjusting the flow of energy. Chief: Eating dysphoria, timidness, blood deficiency, etc.
ガイキョウケツ:チワン族医薬名はyazgyanghgezであり、ウラボシ科植物カザリシダPseudodrynaria coronans (Wall.) Chingの根茎に由来する。性味:苦、熱。効能:腎の働きを向上させて、筋骨を丈夫にし、龍路を整えて、痛みを止める。主治:泄瀉、腰痛、風湿骨痛、風火歯痛などである。 Ginkgo citrus: The Zhuang family medicine name is yazgyangghez, and it is derived from the rhizome of Pseudodrynaria coronans (Wall.) Ching. Taste: bitter, fever. Efficacy: Improves the function of the kidneys, strengthens the muscles and bones, prepares the dragon road, and stops pain. Main cause: Excretion, low back pain, wind and bone pain, wind and toothache.
オウキャクガイ:チワン族医薬名はGaekdinbitであり、キク科植物ヨモギナArtemisia lactiflora Wall.ex DC.の全草に由来する。性味:辛、苦、熱。効能:谷道を整え、湿毒を取り除く。主治:生理痛、無月経、胃痛、慢性胃炎、肝脾腫大、食滞、泄瀉、ヘルニア、固根、打撲傷、火傷や熱傷などである。 Pleurotus chinensis: The Zhuang family medicine name is Gaekdinbit, and the Asteraceae plant Artemisia lactiflora Wall. ex DC. Derived from the whole plant. Taste: Spicy, bitter, fever. Efficacy: Cleans the valley and removes the poison. Main cure: Menstrual pain, amenorrhea, gastric pain, chronic gastritis, hepatosplenomegaly, eating swelling, excretion, hernia, roots, bruises, burns and burns.
ニッケイ:チワン族医薬名はNaengigveqであり、クスノキ科植物シナニッケイCinnamomum cassia Preslの茎皮に由来する。性味:辛、甘、熱。効能:水道を整えて、虚の状態を改善し、湿邪を取り除く。主治:気虚、血虚、陽萎、淋証、面赤足冷、めまいや耳鳴、口舌糜破、胃痛、泄瀉、腰痛、無月経、生理痛、悪性潰瘍、癰腫などである。 Nikkei: The name of the Zhuang family is Naengigveq, which is derived from the stem bark of the camphoraceous plant Cinnamomum cassia Presl. Taste: Spicy, sweet, heat. Efficacy: Prepare the water supply, improve the condition of emptiness and remove the cold. Main cures: Qi deficiency, blood deficiency, atrophy, gonorrhoea, cold red feet, dizziness and tinnitus, erosion of the tongue, gastric pain, excoriation, back pain, amenorrhea, menstrual pain, malignant ulcers, and phlegm.
シシ:チワン族医薬名はGanodermaであり、多孔菌科真菌ガノダーマシネンスGanodernau sinen Zhao.Xu et zhangの子実体に由来する。性味:甘、平。効能:龍路、谷道を整え、気の流れを調整して虚の状態を改善する。主治:気虚、血虚、不眠、眩暈、咳、喘息などである。 Shishi: The name of the Zhuang family medicine is Ganoderma, and the porosomycete fungus Ganoderma sinenzin Zhao. It is derived from the fruiting body of Xu et zhang. Taste: sweet, flat. Efficacy: Ryoji and valley roads are arranged to adjust the flow of energy and improve the state of imagination. Main cure: Qi, blood, insomnia, dizziness, cough, asthma, etc.
シャキョウ:チワン族医薬名はSagiengであり、ショウガ科植物バンウコンKaempferia galangalの根茎に由来する。性味:辛、熱。効能:湿毒を取り除き、谷道を整え、痛みを止める。主治:胃痛、嘔吐、泄瀉、コレラ、食滞、歯痛、風湿骨痛などである。 Shakyo: The Zhuang medicine name is Sagieng, which is derived from the rhizome of the ginger family Kaempferia galangal. Taste: Spicy, fever. Efficacy: Removes wet poison, prepares valleys and stops pain. Main cure: Stomach pain, vomiting, excoriation, cholera, eating sickness, toothache, wind and wet bone pain.
キキョウ:チワン族医薬名はGitgwngqであり、キキョウ科植物キキョウPlatycodon grandiflorus (Jacq.) A.DC.の根に由来する。性味:苦、辛、平。効能:気道を整える。主治:咳、喀痰、咽頭痛、悪性潰瘍、癰腫、赤痢、尿閉などである。 Kyoukyo: The name of the Zhuang family medicine is Gitgwngq, and it is a plant belonging to the family Cynodonaceae Platycodon grandiflorus (Jacq.) A. DC. Derived from the root of. Taste: Bitter, spicy, flat. Efficacy: Prepares the airway. Main cause: Cough, sputum, sore throat, malignant ulcer, sputum, dysentery, urinary retention.
処方におけるオウカトウスイレン、ホウトウクウは主薬であり、ガイキョウケツ、オウキャクガイ、ニッケイは副薬であり、シシ、シャキョウは公薬であり、キキョウは母薬であり、処方全体は、主副公母を組み合わせて使用し、気の流れを調整して虚の状態を改善し、龍路、火路を整える効能を果たす。 In the prescription, Okato Suiren, Hakutou are the main drugs, Gaikyotsutsu, Okukakui, Nikkei are the side drugs, Shishi and Shakyo are the public drugs, Kykyo are the mother drugs, and the whole prescription is a combination of the main and sub-parents. It is used to adjust the flow of energy and improve the state of emptiness, and it has the effect of adjusting dragon roads and fire paths.
本発明は、以下の顕著な効果を有する。 The present invention has the following remarkable effects.
本発明は、気の流れを調整して虚の状態を改善し、龍路、火路を整えるという明確な効能を有し、精神不振、神気虚耗、精神的・体力的疲労、少気懶言、声低息微などの症状をよりよく改善する補気・精神調節用チワン族医薬品組成物を提供し、その調製方法も提供し、調製方法は、操作しやすく、生薬の効能を十分に発揮することができる。 INDUSTRIAL APPLICABILITY The present invention has the clear effects of adjusting the flow of qi to improve the state of imagination, preparing the dragon road and the fire tract, and impairing mental health, exhaustion of spirits, mental and physical fatigue, and apathy Provide a Zhiwan pharmaceutical composition for aspiration/psychoregulation that improves symptoms such as vergence and low breathiness, and provides a method for preparing the composition, which is easy to operate and has sufficient efficacy of crude drugs. Can be demonstrated to.
以下、実施例により本発明をさらに説明するが、本発明の保護範囲を限定するものではない。 Hereinafter, the present invention will be further described with reference to Examples, but the scope of protection of the present invention is not limited thereto.
補気・精神調節用チワン族医薬品組成物の調製プロセス
(一)生産プロセスの設計
本処方は、臨床的経験に基づく処方であり、剤形として一般的に煎剤を使用し、製造方法が簡単であり、機器の条件により制限されないような利点を有する。しかし、煎剤は、ほとんど単剤として煎じたものであり、品質の統一及び量産が難しく、保存しにくく、携帯や輸送が不便であり、使用も不便である。上記欠点を解決し、大多数の患者により受け取られやすくするために、一般的な投与経路及び方法に適している剤形である顆粒剤を、本製品の調製剤形とする。伝統的な漢方薬の煎剤は、水を抽出溶媒とすることが多く、水による抽出は、コストが低く、薬効が確かであるため、水を抽出溶媒とする予定である。生産プロセスの方法は、水で煎じて、乾燥ペーストを得た後、賦形剤を加え、造粒することである。
Preparation process of Zhuang pharmaceutical composition for replenishment/psychotherapy (1) Design of production process This formula is a formula based on clinical experience. Generally, decoction is used as the dosage form and the manufacturing method is simple. There is an advantage that it is not limited by the conditions of the device. However, most of the decoctions are decocted, and it is difficult to unify their quality and mass-produce them, it is difficult to store them, they are inconvenient to carry and transport, and they are inconvenient to use. In order to solve the above-mentioned drawbacks and make it easier to be received by the majority of patients, granules, which is a dosage form suitable for general administration routes and methods, is used as a preparation dosage form of the product. Water is often used as an extraction solvent for traditional Chinese medicine decoctions, and water extraction is planned to use water because the cost is low and the drug efficacy is certain. The method of the production process is to decoct with water to obtain a dry paste, then add excipients and granulate.
(二)水抽出プロセス条件のスクリーニング
1、直交試験の設計
水抽出効果に影響を及ぼす要因は、(1)煎じ回数、(2)煎じ時間、(3)水添加量、(4)破砕度である。3水準で、これらの要因について、直交試験の最適化を実行し、L9(34)直交表を用いて直交試験を実行した(詳細は表1、表2を参照)。
(2) Screening of water extraction process conditions 1. Design of orthogonal test The factors that influence the water extraction effect are (1) number of decoctions, (2) decoction time, (3) water addition amount, and (4) crushing degree. is there. In three levels, (see details in Table 1, Table 2) for these factors, and performing an optimization of the orthogonal test, L 9 (3 4) was performed orthogonal test using an orthogonal table.
2、最適化指標及び総合スコアリング方法
本製品の処方には、抽出する必要がある生薬は合計8つであり、そのうち、君薬は、オウカトウスイレンであり、フラボノイド成分を主に含有し、その代表的な成分は総フラボンであり、総フラボンの含有量のレベルは本製品の有効性と密に関連し、本製品のプロセス条件の最適化指標とすることができ、エキス収率は、抽出効率を全体的に反映することができ、本製品のプロセス条件の第2の最適化指標とした。主成分の重み係数が大きいという原則に準じて、総サポニン含有量を主(重み係数0.6)、エキス収率を補助とし(重み係数0.4)、以下の式1、2によりスコアリングした。以下の簡単な式3により総合スコアリングを行った。
式1、総フラボン含有量=抽出された総サポニン量/生薬の質量×100%
式2、エキス収率=エキス重量/生薬の質量×100%
式3、dij=b1aij/s1+b2bij/s2+b3cij/s3
式中、aij、bij、cijは第i項の第jの指標であり、s1、s2、s3はサンプルの標準偏差であり、b1、b2、b3は重み係数である。
2. Optimization index and total scoring method There are a total of 8 crude drugs that need to be extracted in the prescription of this product, of which the medicinal product is eucato sirren, which mainly contains flavonoid components, Its typical component is total flavone, and the level of total flavone content is closely related to the effectiveness of this product, which can be an optimization index for the process conditions of this product, and the extract yield is It was possible to reflect the extraction efficiency as a whole and was used as the second optimization index for the process conditions of this product. According to the principle that the weighting factor of the main component is large, the total saponin content is mainly (weighting factor 0.6), the extract yield is assisted (weighting factor 0.4), and the scoring is performed by the following equations 1 and 2. did. Overall scoring was performed according to the following simple formula 3.
Formula 1, total flavone content=total amount of saponin extracted/mass of crude drug×100%
Formula 2, extract yield=extract weight/crude drug mass×100%
Formula 3, dij=b1aij/s1+b2bij/s2+b3cij/s3
In the formula, aij, bij, and cij are the j-th index of the i-th term, s1, s2, and s3 are standard deviations of samples, and b1, b2, and b3 are weighting factors.
3、最適化方法
3.1直交試験
表2に示される直交設計試験表に従って試験を設定し、各群の試験では、処方量の生薬を準備し、各試験番号の煎剤をそれぞれ合わせ、均一に混合し、濾過し、濾液を濃縮した後、1000mlに定容し、試験液とした。
3. Optimization method 3.1 Orthogonal test The test is set up according to the orthogonal design test table shown in Table 2, and in the test of each group, the prescribed amount of crude drug is prepared, and the decoctions of the respective test numbers are combined and uniformly. After mixing, filtering, and concentrating the filtrate, the volume was adjusted to 1000 ml to obtain a test solution.
3.2測定方法
総固形分の測定
試験液100mlを精密に量り、105℃で一定重量まで乾燥した蒸発皿に入れ、水浴で蒸乾し、80℃で一定重量まで減圧乾燥し、重量を秤量して、乾燥ペーストの量を算出した。
3.2 Measurement method Total solid content measurement 100 ml of the test solution was precisely weighed, placed in an evaporation dish dried to a certain weight at 105°C, steam-dried in a water bath, and dried under reduced pressure to a certain weight at 80°C, and weighed. Then, the amount of dry paste was calculated.
総フラボン含有量の測定
1、試薬
1.1 ポリアミド粉末
1.2 ルチン標準溶液
ルチン5.0mgを秤取し、メタノールを加えて溶解し、100mlに定容し、50μg/mlを得た。
1.3 エタノール:分析グレード
1.4 メタノール:分析グレード
Measurement of total flavone content 1. Reagents
1.1 Polyamide powder
1.2 Rutin standard solution 5.0 mg of rutin was weighed and dissolved by adding methanol to a constant volume of 100 ml to obtain 50 μg/ml.
1.3 Ethanol: analytical grade
1.4 Methanol: analytical grade
2、分析ステップ
2.1 試料の処理:サンプルから水を蒸発させた乾燥ペースト試料を1.5g秤取し、エタノールを加え、2mlに定容し、均一に振り、20min超音波抽出し、放置し、上清液を1.0ml吸い取り、蒸発皿にポリアミド粉末を1g加えて吸着させ、水浴においてエタノールを蒸発させ、その後、クロマトグラフィーカラムに移した。先ず、20mlのベンゼンで洗浄し、ベンゼン溶液を捨て、次に、メタノールでフラボンを溶出し、25mlに定容した。この溶液について波長360nmで吸収値を測定した。同時に、ルチンを標準品とし、検量線を決定し、回帰式を求め、試料中の総フラボンの含有量を算出した。
2. Analysis step 2.1 Sample treatment: Weigh 1.5 g of dry paste sample obtained by evaporating water from the sample, add ethanol to constant volume to 2 ml, shake evenly, ultrasonically extract for 20 min, and let stand. Then, 1.0 ml of the supernatant was sucked up, and 1 g of polyamide powder was added to the evaporation dish for adsorption, and ethanol was evaporated in a water bath, and then transferred to a chromatography column. First, it was washed with 20 ml of benzene, the benzene solution was discarded, and then flavone was eluted with methanol to a fixed volume of 25 ml. The absorption value of this solution was measured at a wavelength of 360 nm. At the same time, using rutin as a standard product, a calibration curve was determined, a regression equation was determined, and the content of total flavone in the sample was calculated.
2.2 ルチン検量線
ルチン標準溶液0、1.0、2.0、3.0、4.0、5.0mlを10ml比色管に吸い取り、メタノールを所定の目盛りまで加え、均一に振り、波長360nmで比色した。回帰式を求め、試料中の総フラボンの含有量を算出した。
2.2 Rutin calibration curve Rutin standard solution 0, 1.0, 2.0, 3.0, 4.0, 5.0 ml is sucked into a 10 ml colorimetric tube, methanol is added to a predetermined scale and shaken evenly. Color comparison was performed at a wavelength of 360 nm. A regression equation was obtained and the content of total flavones in the sample was calculated.
3、計算及び結果:
式中、
X−試料中の総フラボンの含有量(mg/100g)
A−検量線より算出された試験液中のフラボンの量(μg)
M−試料の質量(g)
V1−測定用試料体積(ml)
V2−試料定容総体積(ml)
計算結果は、有効数字2桁であった。
3, calculation and results:
In the formula,
X-content of total flavones in the sample (mg/100g)
A-Amount of flavone in the test solution calculated from the calibration curve (μg)
M-mass of sample (g)
V 1- volume of sample for measurement (ml)
V 2 - sample constant volume total volume (ml)
The calculation result was two significant digits.
4、直交試験最適化の結果及び分析
結果に対して総合スコアリングを行い、スコアリング結果に対して視覚分析及び分散分析を行い、結果を表4、5に示した。明らかなように、A、B、Cの3つの要因は、いずれもエキス収率、総フラボンの含有量に影響を及ぼし、影響要因の順序は、B>A>Cであり、分散分析結果から、差異が有意であることを示した。また、多重比較により、水抽出の最適な理論抽出条件は、好ましくは、B3A1C1、即ち、処方量10倍の水を加え、1回1h、3回抽出する。
表1 水抽出プロセスL9(34)直交試験設計及び結果(n=2)
表2 水抽出プロセスの分散分析表
注、F0.01(1,2)=99、F0.05(1,2)=19
4. Comprehensive scoring was performed on the results of orthogonal test optimization and analysis results, and visual analysis and analysis of variance were performed on the scoring results. The results are shown in Tables 4 and 5. As is clear, the three factors A, B, and C all affect the extract yield and the total flavone content, and the order of the influencing factors is B>A>C. , Showed that the difference was significant. The optimum theoretical extraction condition for water extraction by multiple comparison is preferably B3A1C1, that is, water with a prescription amount of 10 times is added, and extraction is performed once for 1 h and 3 times.
Table 1 Water extraction process L 9 (3 4 ) orthogonal test design and results (n=2)
Table 2 ANOVA table for water extraction process
Note, F 0.01 (1,2)=99, F 0.05 (1,2)=19
5、直交試験最適化結果の確認試験
上記プロセスに従って3回煎じた煎じ滓に10倍の水を加え、1時間煎じ、煎剤を濾過し、1000mlまで濃縮し、50mlを精密に量り、上記総フラボンの含有量の測定方法に従って測定した結果、総フラボンの含有量が非常に低く、乾燥ペーストが1.5%得られ、それは、生薬を3回煎じると、有効成分が基本的に抽出されることを示した。
5. Confirmation test of the orthogonal test optimization result Add 10 times water to the decoction decocted three times according to the above process, decoct for 1 hour, filter the decoction, concentrate to 1000 ml, accurately weigh 50 ml, and add the total flavone. The total flavone content is very low and 1.5% dry paste is obtained according to the method of measuring the content of the above, which means that the active ingredient is basically extracted when the crude drug is decocted 3 times. showed that.
(三)濃厚ペーストの乾燥プロセスの最適化
最適化した水抽出プロセスで本製品を濃縮した濃厚ペーストを、70℃、80℃、90℃で一定重量まで減圧乾燥し、乾燥ペーストを約1g、精密に秤量し、上記総フラボンの測定方法に従ってサンプルソラレンの含有量を測定し、結果を表3に示した。実験結果から、乾燥温度は、本製品の総フラボンの含有量に影響を及ぼし、80℃での減圧乾燥が最適であり、ソラレン含有量を低下させることなく作業効率を向上できることを示し、これにより、濃厚ペーストの乾燥温度条件として、80℃で減圧乾燥することとした。
表3、濃厚ペーストの乾燥温度試験
(3) Optimization of the drying process of concentrated paste The concentrated paste obtained by concentrating this product by the optimized water extraction process is dried under reduced pressure at 70°C, 80°C, and 90°C to a constant weight, and the dried paste is approximately 1 g, precise. The sample psoralen content was measured according to the above total flavone measurement method, and the results are shown in Table 3. The experimental results show that the drying temperature affects the total flavone content of this product, vacuum drying at 80°C is optimal, and the working efficiency can be improved without lowering the psoralen content. As a drying temperature condition of the thick paste, it was decided to perform reduced pressure drying at 80°C.
Table 3, Drying temperature test of thick paste
(四)造粒成形プロセスの最適化についての検討
最適な抽出プロセスに従って得られた薬液を濃縮乾燥し、エキス粉末を得て、賦形剤をエキス粉末と均一に混合して顆粒に製造したときの収率、溶解度及び口当たりに応じて適切な賦形剤を選択した。結果を表4−1に示した。
顆粒収率の測定:調製された顆粒を秤量した。顆粒収率=合格顆粒の重量g/(エキス粉末の重量g+賦形剤の重量g)×100%
溶解度の測定:一定重量まで乾燥した5mL遠心分離管に精密に秤量した顆粒を加え、沸騰水5mLを精密に加え、5min撹拌して振とうし、3000r/minで15min遠心分離し、上清液を捨て、80℃で残渣を一定重量まで乾燥し、精密に秤量し、溶解率を算出した。溶解率=溶解顆粒の質量/顆粒の質量×100%
口当たり等級:重苦味、微苦味を伴う甘味。
表4−1 賦形剤のスクリーニング結果
賦形剤のスクリーニング実験結果より、賦形剤をスクロースとした。
成形プロセスについての検討:
成形プロセスに影響を及ぼす多くの要因のうち、エタノールの濃度、エタノールの使用量及び撹拌時間を考慮して要因レベル及びL9(34)直交試験表を設計し、表2−2、表2−3として示した。成形性を評価指標とした。
表4−2 要因レベル表
表4−3 L9(34)直交試験表
表4−4 分散分析結果
注:F0.05(2.2)=19.00
分散分析結果から、顆粒収率に対する3つの要因の影響の度合いは、A>B>Cであり、要因A、Bには有意であることがわかった。視覚分析の結果により、最適なプロセスはA2B2C3であることを確認し、最適なプロセス条件A2B2C3試験を繰り返したところ、顆粒収率が直交表の試験結果とほぼ一致した。表4−5を参照されたい。従って、成形プロセスを、エタノール濃度75%、エタノール使用量8%、15min撹拌とした。
表4−5 検証実験結果リスト(n=3)
(4) Study on optimization of granulation molding process When the drug solution obtained according to the optimum extraction process is concentrated and dried to obtain an extract powder, and an excipient is uniformly mixed with the extract powder to produce granules. Appropriate excipients were selected depending on the yield, solubility and mouthfeel of the. The results are shown in Table 4-1.
Measurement of granule yield: The prepared granules were weighed. Granule yield=weight of accepted granules/(weight of extract powder g+weight of excipients g)×100%
Solubility measurement: Add precisely weighed granules to a 5 mL centrifuge tube that has been dried to a certain weight, add 5 mL of boiling water accurately, shake for 5 minutes, shake, centrifuge at 3000 r/min for 15 minutes, and then remove the supernatant. Was discarded, the residue was dried to a constant weight at 80° C., weighed precisely, and the dissolution rate was calculated. Dissolution rate = mass of dissolved granules / mass of granules x 100%
Mouthfeel grade: Sweetness with heavy bitterness and slight bitterness.
Table 4-1 Excipient screening results
Based on the results of the screening experiment for excipients, the excipient was sucrose.
Consideration of molding process:
Of the many factors affecting the molding process, the concentration of ethanol, the amount and factor levels in consideration of the stirring time and L 9 ethanol (3 4) Design the orthogonal test table, Table 2-2, Table 2 -3. The moldability was used as an evaluation index.
Table 4-2 Factor level table
Table 4-3 L 9 (3 4 ) orthogonal test table
Table 4-4 Analysis of variance results
Note: F 0.05 (2.2)=19.00
From the analysis of variance analysis, it was found that the degree of influence of the three factors on the granule yield was A>B>C, and the factors A and B were significant. From the results of visual analysis, it was confirmed that the optimum process was A 2 B 2 C 3 , and when the optimum process condition A 2 B 2 C 3 test was repeated, the granule yield was almost the same as the test result in the orthogonal table. Matched See Tables 4-5. Therefore, the molding process was carried out with an ethanol concentration of 75%, an ethanol usage amount of 8%, and stirring for 15 minutes.
Table 4-5 List of verification experiment results (n=3)
(五)パイロットテストについての検討
スクリーニングされた処方プロセスに従って、100倍拡大し、3つのパイロットテストを実行し、そのバッチ番号を、それぞれ20180401、20180402、20180403とした。各バッチには、100000gの比率で原料を秤取した。8倍量の水を加え、1回当たり60minに、3回抽出し、濾過して濃縮し、真空乾燥し、粉砕して100メッシュのふるいにかけ、乾燥ペースト粉末に、100000gまでスクロースを加え、均一に混合し、75%エタノールを用いて軟質材料とし、12メッシュのふるいにかけて造粒し、75℃で4h乾燥し、12メッシュのふるいにかけて整粒し、混合機で均一に混合し、梱包して包装し、得られた顆粒サンプルの顆粒収率、粒度及び溶解度をそれぞれ統計し、得られた結果を表に示した。
表5 3バッチのパイロットテスト結果
(5) Examination of pilot test According to the screened prescription process, 100 times expansion was performed, three pilot tests were performed, and their batch numbers were set to 20188041, 20120402, and 20180403, respectively. Raw materials were weighed in a ratio of 100,000 g in each batch. Add 8 times amount of water, extract 3 times for 60 min each time, filter, concentrate, vacuum dry, crush and sieve with 100 mesh, add sucrose up to 100000g to dry paste powder, homogenize To 75% ethanol to make a soft material, granulate with a 12 mesh sieve, dry at 75°C for 4 h, sieving with a 12 mesh sieve, mix evenly with a mixer and package. The granule yield, particle size and solubility of each of the obtained granule samples after packaging were statistically analyzed, and the obtained results are shown in the table.
Table 5 Results of 3 batch pilot test
(六)安定性調査試験
本製品の包装、貯蔵、輸送中の安定性を検討し、製剤の有効期限を設定する基礎を提供するために、『漢方薬、天然薬物安定性研究の技術指導原則』に記載の要件に従って、顆粒剤安定性試験の関連規定及び本製品の品質基準のドラフトにより、龍鑽通痺顆粒の3バッチのサンプルについて、加速安定性試験及び長期安定性試験を実行した。本製品について12ヶ月の長期常温調査及び6ヶ月の加速安定性調査を行った結果、3バッチのサンプルの性状、同定、検査、含有量測定及び微生物限界検査は、いずれも規定を満たした。この結果から、本製品の有効期間は、暫定的に2年に設定できることを示し、貯蔵条件は30℃±2℃であり、相対湿度は65%±5%であり、低密度ポリエチレン医薬品包装用複合フィルムを包装材料とした。
(6) Stability investigation test In order to provide a basis for studying the stability of this product during packaging, storage, and transportation, and to set the expiration date of the drug product, "Technical Guiding Principles for Stability Studies of Chinese Herbs and Natural Drugs" Accelerated stability test and long-term stability test were carried out on samples of 3 batches of Ryurantsugran granule according to the requirements of the granule stability test and the draft of the quality standard of this product according to the requirements described in 1. As a result of conducting a long-term room temperature investigation for 12 months and an accelerated stability investigation for 6 months on this product, the properties, identification, inspection, content measurement and microbial limit inspection of 3 batches of samples all satisfied the regulations. From this result, it is shown that the shelf life of this product can be provisionally set to 2 years, the storage condition is 30°C ± 2°C, the relative humidity is 65% ± 5%, and it is used for packaging low-density polyethylene pharmaceuticals. The composite film was used as the packaging material.
(七)結論
補気・精神調節用チワン族医薬品組成物の最適な調製プロセスは、生薬に水を10倍加え、1回当たり1時間に3回煎じ、濾過して濃縮し、80℃で減圧乾燥し、粉砕して100メッシュのふるいにかけ、乾燥ペースト粉末にスクロースを加え、均一に混合し、75%エタノールを用いて軟質材料とし(エタノール使用量8%)、15min撹拌し、12メッシュのふるいにかけて造粒し、75℃で4h乾燥し、12メッシュのふるいにかけて整粒し、混合機で均一に混合し、梱包して包装することである。
(7) Conclusion The optimal process for preparing a Zhuang pharmaceutical composition for replenishment/psychotherapy is to add 10 times water to crude drug, decoct 3 times per hour, filter, concentrate, and depressurize at 80°C. Dry, crush and sieving with a 100 mesh sieve, add sucrose to the dry paste powder, mix evenly, use 75% ethanol as a soft material (ethanol usage 8%), stir for 15 min, and sieve with 12 mesh. Granulate over 4 hours, dry at 75° C. for 4 hours, size through a 12 mesh sieve, mix evenly with a mixer, package and package.
二、臨床実施例
実施例1
1.チワン族医薬品組成物は、重量部で、オウカトウスイレン40g、ホウトウクウ40g、ガイキョウケツ20g、オウキャクガイ20g、ニッケイ10g、シシ20g、シャキョウ20g、キキョウ20gの原料を含む。
Second, clinical example Example 1
1. The Zhiwan pharmaceutical composition contains, by weight, 40 g of Oukatousuren, 40 g of Ganoderma lucidum, 20 g of Gyokyoketsu, 20 g of Ganoderma lucidum, 10 g of Nikkei, 20 g of Shishi, 20 g of Ginger, and 20 g of Ginger.
2.チワン族医薬品組成物の調製方法:
上記原料を重量に応じてそれぞれ秤取し、原料を洗浄して選別し、薬鍋に入れ、一次煎じを行い、具体的には、水を加え、0.5〜1時間浸し、薬液が沸騰するまで強火で煎じた後、弱火に切り替えて20〜25分間煎じ、煎じ汁を濾取し、二次煎じを行い、具体的には、薬鍋に生薬の平面から0.5〜1センチメートル上に常温の水を再度加え、薬液が沸騰するまで強火で煎じた後、弱火に切り替えて15〜20分間煎じ、煎じ汁を濾取し、一次煎じと二次煎じで得られた煎じ汁を合わせた。本発明によるチワン族医薬品組成物は、煎剤であった。
2. Method for preparing Zhuang pharmaceutical composition:
The above raw materials are weighed according to weight, washed and sorted, put in a pot for primary decoction, specifically, water is added and soaked for 0.5 to 1 hour to boil the chemical liquid. After decocting until high, switch to low heat and decoct for 20 to 25 minutes, filter the decoction and perform secondary decoction, specifically, 0.5 to 1 cm from the plane of the crude drug in a medicinal pot. After adding water at room temperature again and decocting over high heat until the chemical solution boils, switch to low heat and decoct for 15 to 20 minutes, filter the decoction, and extract the decoction obtained from the primary decoction and the secondary decoction. I matched it. The Zhuang pharmaceutical composition according to the present invention was a decoction.
3.投薬方法:上記顆粒剤を経口投与し、1剤/日、朝晩1回ずつ服用し、14日間を1クールとし、2クール連続して治療した。 3. Dosing method: The above-mentioned granules were orally administered, and one drug/day was taken once a day in the morning and once a day for 14 days, and 1 course was taken for 14 days, and 2 courses were continuously treated.
4.典型的な病例:
黎氏、女性、41歳、河池市人、気虚、精神不振3年、上記投薬方法に従って、このチワン族医薬品組成物を服用した後、症状が好転した。
牛氏、女性、37歳、玉林市人、気虚、精神不振6年、上記投薬方法に従って、このチワン族医薬品組成物を服用した後、症状が好転した。
4. Typical cases:
Mr. Rei, female, 41 years old, Ichito Kawaike, timidness, mental illness 3 years, after taking this Zhuang pharmaceutical composition according to the above-mentioned administration method, the symptoms improved.
Mr. Ushi, female, 37 years old, Ichijin Tamabayashi, spirit, mental illness 6 years, after taking this Zhuang family pharmaceutical composition according to the above-mentioned administration method, symptoms improved.
実施例2
1.チワン族医薬品組成物は、重量部、オウカトウスイレン40部、ホウトウクウ40部、ガイキョウケツ20部、オウキャクガイ20部、ニッケイ10部、シシ20部、シャキョウ20部、キキョウ20部の原料を含む。比率は、4:4:2:2:1:2:2:2であった。
Example 2
1. The Zhuang family pharmaceutical composition contains parts by weight, 40 parts of Oukatousuren, 40 parts of Shiratou, 20 parts of oyster butter, 20 parts of oyster oyster, 10 parts of nikkei, 20 parts of shisha, 20 parts of kyokyo, and 20 parts of kyokyo. The ratio was 4:4:2:2:1:2:2:2.
2.チワン族医薬品組成物の調製方法:
重量部で秤取された上述の原料をそれぞれ洗浄して選別した後、生薬に水を10倍加え、1回当たり1時間に3回煎じ、濾過して濃縮し、80℃で減圧乾燥し、粉砕して100メッシュのふるいにかけ、乾燥ペースト粉末にスクロースを加え、均一に混合し、75%エタノールを用いて軟質材料とし(エタノール使用量8%)、15min撹拌し、12メッシュのふるいにかけて造粒し、75℃で4h乾燥し、12メッシュのふるいにかけて整粒し、混合機で均一に混合し、梱包して包装し、パックあたり25gとした。
2. Method for preparing Zhuang pharmaceutical composition:
After washing and selecting each of the above-mentioned raw materials weighed in parts by weight, water is added to the crude drug 10 times, and the crude drug is decocted 3 times per hour, filtered, concentrated, and dried under reduced pressure at 80° C., Pulverize and pass through a 100-mesh sieve, add sucrose to the dry paste powder, mix evenly, make a soft material using 75% ethanol (ethanol usage 8%), stir for 15 min, and granulate through a 12-mesh sieve. Then, it was dried at 75° C. for 4 hours, sized with a 12-mesh sieve, uniformly mixed with a mixer, packed and packaged to give 25 g per pack.
3.投薬方法:上記顆粒剤を、1パック/回、朝晩1回ずつ経口投与し、14日間を1クールとし、2クール連続して治療した。 3. Dosing method: The above granules were orally administered once per pack, once in the morning and once in the morning, and treated for 14 days with 1 course and 2 courses continuously.
4.本発明の薬物を使用した患者についての臨床的な統計資料:
4.1基本資料
診断基準:(1)現代医学診断基準(『亜健康漢方医臨床ガイド』の診断基準に従って策定)を参照し、被験者の主訴により、精神的・体力的疲労、少気懶言、声低息微などの不快感は、3ヶ月以上繰り返し発作し、重要な器質的疾患や精神疾患はなく、投薬を必要とせず、関連する実験室及び身体検査では陽性結果はない。(2)漢方医証候診断基準(2002版『新しい漢方薬の臨床研究指導原則』)を参照し、気虚の主症は、息切れ、疲労、倦怠感、脈虚であり、次症は、自汗、懶言、舌淡であり、2つの主症+1つの次症を持っている人は気虚であると判定された。亜健康診断基準及び漢方医漢方医血虚証基準基準を満たした患者は、男性56例、女性64例、合計120例であり、年齢30〜50歳、病状3〜10年であった。
4. Clinical statistical data on patients using the drug of the present invention:
4.1 Basic data Diagnostic criteria: (1) Refer to the modern medical diagnostic criteria (developed according to the diagnostic criteria of the "Ahealth Chinese Medicine Clinical Guide"), and the subject's chief complaint indicates mental/physical fatigue and low temper , Discomfort, such as low-pitched breathing, repeats seizures for more than 3 months, has no significant organic or mental illness, requires no medication, and has no positive laboratory and physical examination results. (2) With reference to Kampo medicine diagnostic criteria (2002 version, "Principles for Clinical Research on New Kampo Medicines"), the main symptom of Qi Feng is shortness of breath, fatigue, malaise and pulsation. A person who has sweat, fluency, and tongue and has two main symptom + one secondary symptom was judged to be sick. The total number of patients who met the sub-health examination criteria and the Kampo medicine Kampo medicine blood deficiency criteria criteria was 56 for men and 64 for women, a total of 120 cases, and the age was 30 to 50 years and the medical condition was 3 to 10 years.
4.2実験の群分け
患者を、観察群と、対照群の2群にランダムに分け、各群を60人とした。
4.2 Grouping of Experiments Patients were randomly divided into two groups, an observation group and a control group, and each group had 60 patients.
4.3治療計画
観察群:上記顆粒剤を、1パック/回、朝晩1回ずつ経口投与し、14日間を1クールとし、2クール連続して治療した。
対照群:オリザノール、ビタミンB1をそれぞれ20mg、1日3回経口投与し、14日間を1クールとし、2クール連続して治療した。
4.3 Treatment plan Observation group: The above-mentioned granules were orally administered once per pack, once in the morning and once in the evening, and treated for 14 consecutive days for 2 courses.
Control group: Oryzanol and Vitamin B1 were orally administered at 20 mg each three times a day, and 14 days were treated as 1 course and 2 courses were treated continuously.
5.治療効果の判定
『漢方医証候の治療効果判定基準』に記載の気虚型亜健康の治療効果判定基準を参照する。短時間治癒:漢方医により診断された症状が消えるか、ほぼ消える。著効:漢方医により診断された症状が大幅に改善される。有効:漢方医により診断された症状がいずれも改善されたが、有意ではない。無効:漢方医により診断された症状がいずれも明らかに改善されず、さらに悪化する。
5. Judgment of therapeutic effect Refer to the judgment criteria of therapeutic effect for qi-type sub-health described in "Criteria for therapeutic effect of Kampo medicine sign". Short-term healing: The symptoms diagnosed by a Chinese medicine doctor disappear or disappear. Remarkable effect: The symptoms diagnosed by Kampo medicine are significantly improved. Efficacy: All symptoms diagnosed by Kampo medicine were improved but not significant. Ineffective: None of the symptoms diagnosed by the Kampo doctor are clearly improved and worsened.
6.統計学的処理
SPSS20.0統計ソフトウェアを用いて分析し、計数資料に対してカイ二乗検定を行い、計量資料に対してt検定を行った。P<0.05の場合は、差には統計的に有意であるとした。
6. Statistical processing The analysis was performed using SPSS20.0 statistical software, the chi-square test was performed on the count data, and the t-test was performed on the measurement data. Differences were considered statistically significant if P<0.05.
7.実験結果
観察群において、32例は短時間治癒、14例は著効、10例は有効、4例は無効であり、総有効率は93.34%であり、対照群において、20例は短時間治癒、9例は著効、11例は有効、20例は無効であり、総有効率は66.67%であった。観察群は、対照群と比較すると、差が統計的に有意であった。観察群の臨床的治療効果は、対照群よりも優れていた。
7. Experimental Results In the observation group, 32 cases were cured for a short time, 14 cases were excellent, 10 cases were effective, 4 cases were ineffective, and the total effective rate was 93.34%. In the control group, 20 cases were short. Time cure, excellent in 9 cases, effective in 11 cases, ineffective in 20 cases, the total effective rate was 66.67%. The difference in the observation group was statistically significant when compared with the control group. The clinical treatment effect of the observation group was superior to that of the control group.
表1 対照群と観察群の臨床的治療効果の比較
注、対照群と比較すると、P<0.05。
Table 1 Comparison of clinical treatment effect between control group and observation group
Note, P<0.05 when compared with the control group.
8.典型的な病例
秦氏、女性、43歳、柳州市人、気虚、精神不振10年、上記投薬方法に従って、このチワン族医薬品組成物を服用した後、症状が好転した。
8. Typical illnesses Mr. Qin, female, 43 years old, Liuzhou city person, timidness, mental illness 10 years, after taking this Zhuang pharmaceutical composition according to the above administration method, the symptoms improved.
黄氏、女性、24歳、賀州市人、気虚、精神不振4年、上記投薬方法に従って、このチワン族医薬品組成物を服用した後、症状が好転した。 Mr. Huang, Female, 24 years old, Hei Jian, Qi, Mental depression 4 years, After taking this Zhuang family pharmaceutical composition according to the above administration method, the symptoms improved.
Claims (4)
ことを特徴とする、補気調節用チワン族医薬品組成物。 10 to 60 parts by weight, 10 to 50 parts by weight, 10 to 40 parts by weight of gall butter, 10 to 30 parts by weight of porcupine, 5 to 20 parts by weight of nikkei, 10 to 25 parts by weight of shish, 10 to 25 parts by weight of shakyo , and are prepared using bellflower 10-30 parts by weight of the raw material,
Characterized in that, Hoki tone paragraph break Zhuang pharmaceutical composition.
ことを特徴とする請求項1に記載の補気調節用チワン族医薬品組成物。 Ou Kato water lily 40 parts by weight, Houtoukuu 40 parts by weight, Gaikyouketsu 20 parts by weight, Oukyakugai 20 parts by weight, 10 parts by weight of cinnamon are prepared using shish 20 parts by weight, council 20 parts by weight, and a balloon flower 20 parts by weight of the raw material ,
Hoki tone paragraph break Zhuang pharmaceutical composition according to claim 1, characterized in that.
ことを特徴とする請求項1又は2に記載の補気調節用チワン族医薬品組成物の調製方法。 After washing each of the raw materials weighed in the above-mentioned parts by weight, water was added to the crude drug 10 times and decocted for 1 hour each time, decocted 3 times, filtered, concentrated, and dried under reduced pressure at 80°C. , Crushed and sieved with 100 mesh, add sucrose to dry paste powder, mix evenly, prepare soft material with ethanol with purity of 75% (ethanol dose is 8%), stir for 15 minutes , and mix with 12 mesh Includes the steps of sieving, granulating, drying at 75° C. for 4 hours , sieving with a 12 mesh sieve, uniform mixing with a mixer, packing and packaging.
Process for the preparation of Hoki tone paragraph break Zhuang pharmaceutical composition according to claim 1 or 2, characterized in that.
ことを特徴とする請求項3に記載の補気調節用チワン族医薬品組成物の調製方法。 The dosage form of the Zhuang pharmaceutical composition is a decoction or a granule,
Process for the preparation of Hoki tone paragraph break Zhuang pharmaceutical composition according to claim 3, characterized in that.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910065453.5 | 2019-01-23 | ||
CN201910065453.5A CN109568525A (en) | 2019-01-23 | 2019-01-23 | A kind of strong drug composition and preparation method thereof of tonifying Qi tune mind |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6708916B1 true JP6708916B1 (en) | 2020-06-10 |
JP2020117493A JP2020117493A (en) | 2020-08-06 |
Family
ID=65917302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020006091A Expired - Fee Related JP6708916B1 (en) | 2019-01-23 | 2020-01-17 | Zhuang family pharmaceutical composition for regulating replenishment and method for preparing the same |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6708916B1 (en) |
CN (1) | CN109568525A (en) |
-
2019
- 2019-01-23 CN CN201910065453.5A patent/CN109568525A/en active Pending
-
2020
- 2020-01-17 JP JP2020006091A patent/JP6708916B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN109568525A (en) | 2019-04-05 |
JP2020117493A (en) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106072626B (en) | It is a kind of towards doctor's compound antler health-care food and its preparation method and application | |
CN102552778B (en) | Medicinal composition for treating cough, and preparation method and application thereof | |
CN107625828A (en) | A kind of health protection tea for auxiliary treatment chronic pharyngitis, preparation method and application | |
CN103315112A (en) | Anti-allergy asthma-relieving tea | |
JP6708916B1 (en) | Zhuang family pharmaceutical composition for regulating replenishment and method for preparing the same | |
CN111991543A (en) | Traditional Chinese medicine composition for severe adjuvant treatment of new coronary pneumonia and preparation method thereof | |
JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
CN104436145A (en) | Pharmaceutical composition for preventing and/or treating allergic rhinitis and allergic asthma | |
CN104771462A (en) | Traditional Chinese medicine for treating chronic bronchitis and preparation method thereof | |
Kumar et al. | Safety and Toxicity of Botanical Medicines: A critical Appraisal | |
CN115645507A (en) | Pure traditional Chinese medicine composition for treating obese type 2 diabetes | |
CN108079169A (en) | For preventing and treating the Chinese medicine composition of atherosclerosis and its complication, Chinese medicine preparation and application | |
CN112206283A (en) | A kind of traditional Chinese medicine composition for relieving physical fatigue and preparation method thereof | |
CN106309758A (en) | Pharmaceutical composition with efficacy of resisting gastrointestinal cancer | |
CN106668329A (en) | Botanical formula for treatment of benign prostatic hyperplasia and preparation method thereof | |
JP6725955B1 (en) | Zhuang pharmaceutical composition for blood supplementation and method for preparing the same | |
CN111558008A (en) | A kind of weight loss and fat-reducing belly button patch, preparation method and application | |
CN105250968A (en) | Traditional Chinese medicine preparation for treating asthma | |
CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
CN118787721B (en) | Pharmaceutical composition for clearing plague and resolving dampness as well as preparation and application thereof | |
CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof | |
CN116849357B (en) | Medicinal and edible composition with liver protection function and preparation method thereof | |
CN101564409B (en) | Application of traditional Chinese indian lettuce in preparation of diabetes drugs | |
CN114259523B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating cough variant asthma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200117 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200117 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200117 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200319 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200407 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200427 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6708916 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |